Naltrexone:
Naltrexone: Overview
Naltrexone is an opioid antagonist medication used to treat opioid use disorder (OUD) and alcohol use disorder (AUD). It helps prevent relapse by reducing cravings and blocking the effects of opioids and alcohol.
Naltrexone is an opioid antagonist medication used to treat opioid use disorder (OUD) and alcohol use disorder (AUD). It helps prevent relapse by reducing cravings and blocking the effects of opioids and alcohol.
Naltrexone is an opioid antagonist medication used to treat opioid use disorder (OUD) and alcohol use disorder (AUD). It helps prevent relapse by reducing cravings and blocking the effects of opioids and alcohol.
Mechanism of Action
|
|
Mechanism of Action
Clinical Benefits
Dosage
Side Effects
Key Considerations
- Opioid Use Disorder:
- Naltrexone competitively binds to mu-opioid receptors in the brain, preventing the effects of opioids such as euphoria and pain relief.
- It blocks the reinforcing properties of opioid use, aiding in relapse prevention.
- Alcohol Use Disorder:
- The exact mechanism in AUD is not fully understood but is believed to involve modulation of the dopaminergic reward system, reducing cravings and the pleasurable effects of alcohol.
Clinical Benefits
- Opioid Use Disorder (OUD):
- Helps prevent relapse after detoxification by blocking opioid effects.
- Non-addictive and does not cause physical dependence.
- Alcohol Use Disorder (AUD):
- Reduces alcohol cravings and heavy drinking episodes.
- Improves abstinence rates when combined with psychosocial support.
Dosage
- Opioid Use Disorder:
- Oral Formulation: 50 mg once daily.
- Extended-Release Injectable: 380 mg intramuscularly every 4 weeks (Vivitrol).
- Alcohol Use Disorder:
- Same dosing as for OUD: oral 50 mg daily or injectable 380 mg monthly.
Side Effects
- Common Side Effects:
- Nausea.
- Fatigue.
- Headache.
- Insomnia.
- Dizziness.
- Less Common Side Effects:
- Anxiety.
- Muscle or joint pain.
- Irritability.
- Serious Side Effects:
- Hepatotoxicity: Dose-dependent liver damage, requiring regular liver function monitoring.
- Precipitated Withdrawal: If started before detoxification from opioids.
- Injection Site Reactions: For extended-release formulations.
Key Considerations
- Contraindications:
- Patients actively using opioids (due to risk of precipitated withdrawal).
- Severe liver disease or acute hepatitis.
- Monitoring:
- Baseline and periodic liver function tests (LFTs).
- Ensure opioid detoxification before initiation.
Sources
- References
- FDA Labeling and Prescribing Information: https://www.accessdata.fda.gov
- National Institute on Alcohol Abuse and Alcoholism (NIAAA):https://www.niaaa.nih.gov
- American Psychiatric Association (APA):
- "Practice Guidelines for the Treatment of Patients with Substance Use Disorders."
- https://psychiatry.org
- MedlinePlus (U.S. National Library of Medicine):https://medlineplus.gov
- Substance Abuse and Mental Health Services Administration (SAMHSA):https://www.samhsa.gov
- National Center for Biotechnology Information (NCBI):
Maisel, N. C., et al. "Meta-analysis of naltrexone for AUD and OUD." https://pubmed.ncbi.nlm.nih.gov - World Health Organization (WHO):
- "Management of Substance Abuse: Medications for Alcohol and Opioid Dependence."
- https://www.who.int